FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2025-11-27
Target enrollment:
Participant gender:
Summary
Phase II, multicenter, single arm trial to assess the feasibility of first line ribociclib in
combination with a non steroidal aromatase inhibitor in women or men aged 70 years-old or
older, with hormone receptor positive/HER2 negative advanced breast cancer